Evidence map›Paper›PMID 42126736›Full record

ReviewDiscover oncology2026

SNARE proteins as biomarkers and therapeutic targets in central nervous system tumors.

Dengzhuo Liu, Jie Li, Zihao Fan, Cheng Zhong, Guangwei Wang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dengzhuo Liu *Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Jie Li *Hunan University of Medicine, Huaihua, Hunan, China.
Zihao FanHengyang Medical School, University of South China, Hengyang, Hunan, China.
Cheng ZhongYoujiang Medical University for Nationalities, Baise, Guangxi, China.
Guangwei WangHengyang Medical School, University of South China, Hengyang, Hunan, China. guangweiwang@hnmu.edu.cn.

Funding

Hunan Provincial Natural Science Foundation of China No. 2024JJ9500The National Key Clinical Specialty Major Scientific Research Project of Hunan Province No. 20230360the National Natural Science Foundation of China No. 81670809the Science and Technology Research Fund of Hunan Provincial Education Department NO.2019JH15
6 · The paper itself

Abstract

Soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins constitute the core molecular machinery that drives intracellular vesicular trafficking and membrane fusion in eukaryotic cells. Beyond their canonical roles in neurotransmitter release, autophagic flux, and exosome secretion, accumulating evidence indicates that dysregulated SNARE expression and function contribute to tumor progression. In central nervous system tumors (CNSTs), aberrant SNARE activity has been increasingly implicated in invasive growth, chemotherapy resistance, and tumor microenvironment remodeling. Guided by the 2021 World Health Organization classification of tumors of the central nervous system (WHO CNS5), this review summarizes current advances on the pathogenic roles of SNARE proteins in glioblastoma, medulloblastoma, meningioma, and pituitary neuroendocrine tumors, and discusses their translational potential as molecular biomarkers and therapeutic targets for precision neuro-oncology.

Indexed as

BiomarkersCentral nervous system tumorsGlioblastomaSNARE

Identifiers

PMID42126736
PMCPMC13341980

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.